Analyse Veradermics, Incorporated (MANE) — Kairos Score 73/100

À propos de Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Veradermics, Incorporated.

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur MANE dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur MANE.

• Veradermics’ stock up on male hair loss trial success
• Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.